A detailed history of Southland Equity Partners LLC transactions in Amgen Inc stock. As of the latest transaction made, Southland Equity Partners LLC holds 1,569 shares of AMGN stock, worth $495,804. This represents 0.12% of its overall portfolio holdings.

Number of Shares
1,569
Previous 1,570 0.06%
Holding current value
$495,804
Previous $491 Million 3.07%
% of portfolio
0.12%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$309.38 - $337.38 $309 - $337
-1 Reduced 0.06%
1,569 $506 Million
Q2 2024

Jul 12, 2024

BUY
$262.75 - $319.31 $2,890 - $3,512
11 Added 0.71%
1,570 $491 Million
Q1 2024

Apr 12, 2024

BUY
$268.87 - $324.56 $5,646 - $6,815
21 Added 1.37%
1,559 $443 Million
Q4 2023

Jan 09, 2024

BUY
$255.7 - $288.46 $8,693 - $9,807
34 Added 2.26%
1,538 $443 Million
Q3 2023

Jan 02, 2024

BUY
$218.65 - $271.46 $41,106 - $51,034
188 Added 14.29%
1,504 $404 Million
Q2 2023

Jan 02, 2024

BUY
$214.27 - $253.37 $2,571 - $3,040
12 Added 0.92%
1,316 $292 Million
Q1 2023

Jan 02, 2024

SELL
$225.79 - $275.2 $26,191 - $31,923
-116 Reduced 8.17%
1,304 $315 Million
Q4 2022

Jan 02, 2024

BUY
$229.03 - $291.01 $97,566 - $123,970
426 Added 42.86%
1,420 $373 Million
Q3 2022

Jan 02, 2024

SELL
$224.46 - $253.15 $4,938 - $5,569
-22 Reduced 2.17%
994 $224 Million
Q2 2022

Jan 02, 2024

BUY
$230.71 - $256.74 $10,151 - $11,296
44 Added 4.53%
1,016 $247 Million
Q1 2022

Jan 02, 2024

BUY
$219.27 - $242.57 $213,130 - $235,778
972 New
972 $235 Million
Q3 2021

Jan 02, 2024

SELL
$212.27 - $248.7 $183,825 - $215,374
-866 Closed
0 $0
Q2 2021

Jan 02, 2024

BUY
$233.58 - $259.14 $1,167 - $1,295
5 Added 0.58%
866 $211 Million
Q1 2021

Jan 02, 2024

BUY
$221.91 - $258.6 $191,064 - $222,654
861 New
861 $214 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Southland Equity Partners LLC Portfolio

Follow Southland Equity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Southland Equity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Southland Equity Partners LLC with notifications on news.